Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)

Expert Review of Clinical Immunology

Volumn 13, Issue 6, 2017, Pages 623-633

  Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

APRIL; atacicept; BAFF; BCMA; belimumab; blisibimod; BR3; tabalumab; TACI

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; BLISIBIMOD; TABALUMAB; AMG623 PEPTIBODY; ANTIINFLAMMATORY AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN; TNFSF13B PROTEIN, HUMAN;

ANCESTRY GROUP; BIOLOGICAL ACTIVITY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; EXPERT WITNESS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EXPERT TESTIMONY; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 85019225067     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2017.1291343     Document Type: Review

References (125)

1. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–3265.
2. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–1756.
3. Moore PA, Belvedere O, Orr A, et al. BLyS:member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260–263.
4. Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192(1):129–135.
5. Do RKG, Hatada E, Lee H, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192(7):953–964.
6. Rolink AG, Tschopp J, Schneider P, et al. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol. 2002;32(7):2004–2010.
7. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3(9):822–829.
8. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111–2114.
9. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease:impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2):289–302.
10. Schneider P, Takatsuka H, Wilson A, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 2001;194(11):1691–1697.
11. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97(1):198–204.
12. Laabi Y, Gras MP, Brouet JC, et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22(7):1147–1154.
13. Von Bülow GU, Bram RJ., NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science. 1997;278(5335):138–141.
14. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293(5537):2108–2111.
15. Yan MH, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11(19):1547–1552.
16. Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol. 2012;188(1):497–503.
17. Kanakaraj P, Migone TS, Nardelli B, et al. BLyS binds to B cells with high affinity and induces activation of the transcription factors NF- κ B and ELF-1. Cytokine. 2001;13(1):25–31.
18. Liu YF, Xu LG, Opalka N, et al. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell. 2002;108(3):383–394.
19. Kim HM, Yu KS, Lee ME, et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol. 2003;10(5):342–348.
20. Liu YF, Hong X, Kappler J, et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature. 2003;423(6935):49–56.
21. Karpusas M, Cachero TG, Qian F, et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol. 2002;315(5):1145–1154.
22. Oren DA, Li YL, Volovik Y, et al. Structural basis of BLyS receptor recognition. Nat Struct Biol. 2002;9(4):288–292.
23. Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood. 2008;111(3):1004–1012.
24. Bossen C, Tardivel A, Willen L, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol. 2011;41(3):787–797.
25. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185–1190.
26. Yu G, Boone T, Delaney J, et al. APRIL and TALL-I and receptors BCMA and TACI:system for regulating humoral immunity. Nat Immunol. 2000;1(3):252–256.
27. Kelly K, Manos E, Jensen G, et al. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res. 2000;60(4):1021–1027.
28. Marsters SA, Yan MH, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol. 2000;10(13):785–788.
29. Wu YM, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem. 2000;275(45):35478–35485.
30. Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000;192(11):1677–1683.
31. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med. 2005;201(1):35–39.
32. Sakurai D, Hase H, Kanno Y, et al. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood. 2007;109(7):2961–2967.
33. He B, Xu W, Santini PA, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26(6):812–826.
34. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008;111(5):2755–2764.
35. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge:the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180(6):3655–3659.
36. Hendriks J, Planelles L, de Jong-Odding J, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005;12(6):637–648.
37. Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005;201(9):1375–1383.
38. Huard B, McKee T, Bosshard C, et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Investig. 2008;118(8):2887–2895.
39. Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol. 2004;24(3):997–1006.
40. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A. 2004;101(11):3903–3908.
41. Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002;169(8):4314–4321.
42. Dillon SR, Harder B, Lewis KB, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010;12(2).
43. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697–1710.
44. Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A. 2000;97(7):3370–3375.
45. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995–999.
46. Jacob CO, Pricop L, Putterman C, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF. J Immunol. 2006;177(4):2671–2680.
47. Jacob N, Guo SH, Mathian A, et al. B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011;186(8):4984–4993.
48. Kayagaki N, Yan MH, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity. 2002;17(4):515–524.
49. Ramanujam M, Wang XB, Huang WQ, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol. 2004;173(5):3524–3534.
50. Ramanujam M, Wang XB, Huang WQ, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Investig. 2006;116(3):724–734.
51. Stein JV, Lopez-Fraga M, Elustondo FA, et al. APRIL modulates B and T cell immunity. J Clin Investig. 2002;109(12):1587–1598.
52. Jacob CO, Guo SH, Jacob N, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012;64(5):1610–1619.
53. Huard B, Tran NL, Benkhoucha M, et al. Selective APRIL blockade delays systemic lupus erythematosus in mouse. Plos One. 2012;7(2).
54. Zhang J, Roschke V, Baker KP, et al. Cutting edge:A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.
55. Cheema GS, Roschke V, Hilbert DA, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313–1319.
56. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus:longitudinal observations. Arthritis Rheum. 2003;48(12):3475–3486.
57. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453–2459.
58. Collins CE, Gavin AL, Migone TS, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus:disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8(1).
59. Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15(9):570–576.
60. Ju SQ, Zhang DL, Wang YG, et al. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem. 2006;39(12):1131–1137.
61. McCarthy EM, Lee RZ, Gabhann JN, et al. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology. 2013;52(7):1279–1284.
62. Petri MA, van Vollenhoven RF, Buyon J, et al. Baseline predictors of systemic lupus erythematosus flares:data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65(8):2143–2153.
63. Cui Y, Sheng YJ, Zhang XJ. Genetic susceptibility to SLE:recent progress from GWAS. J Autoimmun. 2013;41:25–33.
64. Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64(7):1065–1067.
65. Hegazy M, Darwish H, Darweesh H, et al. Raised serum level of APRIL in patients with systemic lupus erythematosus:correlations with disease activity indices. Clin Immunol. 2010;135(1):118–124.
66. Stohl W, Metyas S, Tan SM, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004;63(9):1096–1103.
67. Morel J, Roubille C, Planelles L, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(6):997–1002.
68. Stohl W, Hilbert DM. The discovery and development of belimumab:the anti-BLyS–lupus connection. Nat Biotechnol. 2012;30(1):69–77.• This review chronicles the many hurdles belimumab had to navigate before achieving FDA approval for SLE. Many of these hurdles are not unique to belimumab and may serve as prototypes for hurdles to be faced by other candidate SLE therapeutics.
69. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody:a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5).
70. Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab:pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–154.
71. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–2337.
72. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012;39(8):1632–1640.
73. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(2):300–309.
74. Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288–2295.
75. Iaccarino L, Bettio S, Reggia R, et al. Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 2016. doi:10.1002/acr.22971
76. Fredericks CA, Kvam KA, Bear J, et al. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus. 2014;23(7):711–713.
77. Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus:a systematic literature review. Lupus. 2016;25(6):617–626.
78. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum-Arthritis Care Res. 2009;61(9):1143–1151.
79. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.•• This trial reports the seminal phase-III studies of belimumab in SLE and also laid the foundation for FDA approval of belimumab for SLE, the first drug in 55+ years to have been approved by the FDA for SLE.
80. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930.•• This trial reports the seminal phase-III studies of belimumab in SLE and also laid the foundation for FDA approval of belimumab for SLE, the first drug in 55+ years to have been approved by the FDA for SLE.
81. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus:combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–1838.
82. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes:results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63–72.
83. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus:high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–1349.
84. Roth DA, Thompson A, Tang Y, et al. Elevated BLyS levels in patients with systemic lupus erythematosus:associated factors and responses to belimumab. Lupus. 2016;25(4):346–354.
85. Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings:24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3(1):e000118.
86. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus:A randomized, double-blind, placebo-controlled, 52-week study. Arthritis Rheumatol. 2017. doi:10.1002/art.40049. [Epub ahead of print]• This study reports the efficacy and safety of subcutaneous belimumab, likely leading to FDA approval of a subcutaneous formulation and, thereby, giving patients the option of choosing between intravenous and subcutaneous routes of administration.
87. Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56(12):4142–4150.
88. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18(6):547–555.
89. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis:results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1).
90. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–2015.
91. Hsu H, Khare SD, Lee F, et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin Exp Rheumatol. 2012;30(2):197–201.
92. Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623):results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17.
93. Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74(9):1667–1675.
94. Manetta J, Bina H, Ryan P, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014;7:121–131.
95. Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus:results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–331.
96. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus:results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):332–340.
97. Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A. 2008;105(40):15517–15522.
98. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Investig. 2003;112(2):286–297.
99. Ettinger R, Sims GP, Robbins R, et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007;178(5):2872–2882.
100. Darce JR, Arendt BK, Chang SK, et al. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J Immunol. 2007;178(9):5612–5622.
101. Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74(7):1474–1478.
102. Mitka M. Treatment for lupus, first in 50 years, offers modest benefits, hope to patients. Jama-Journal Am Med Assoc. 2011;305(17):1754–1755.
103. Kawasaki A, Tsuchiya N, Fukazawa T, et al. Analysis on the association of human BLYS (BAFF TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. 2002;3(7):424–429.
104. Eilertsen GO, Van Ghelue M, Strand H, et al. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics:a case-control study. Rheumatology. 2011;50(12):2197–2205.
105. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum-Arthritis Care Res. 2009;61(9):1168–1178.
106. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment:relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54(3):723–732.
107. Cambridge G, Isenberg DA, Edwards JCW, et al. B cell depletion therapy in systemic lupus erythaematosus:relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008;67(7):1011–1016.
108. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2672–2679.• This study offers suggestive evidence to the role of BAFF in driving SLE disease flares in rituximab-treated patients and lays the foundation for clinical trials using rituximab and belimumab as sequential therapy.
109. Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004;20(4):441–453.
110. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785–798.
111. Sasaki Y, Casola S, Kutok JL, et al. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol. 2004;173(4):2245–2252.
112. Shulga-Morskaya S, Dobles M, Walsh ME, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol. 2004;173(4):2331–2341.
113. Harless SM, Lentz VM, Sah AP, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol. 2001;11(24):1986–1989.
114. Jacob CO, Yu N, Guo SH, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013;65(4):1043–1054.
115. Xu SL, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol. 2001;21(12):4067–4074.
116. Jiang C, Loo WM, Greenley EJ, et al. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol. 2011;186(11):6136–6147.
117. Coquery CM, Loo WM, Wade NS, et al. BAFF regulates follicular helper T Cells and affects their accumulation and interferon-γ production in autoimmunity. Arthritis Rheumatol. 2015;67(3):773–784.
118. Ou XJ, Xu SL, Lam KP. Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival. Proc Natl Acad Sci U S A. 2012;109(38):15401–15406.
119. von Bülow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001;14(5):573–582.
120. Yan MH, Wang M, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001;2(7):638–643.
121. Seshasayee D, Valdez P, Yan MH, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003;18(2):279–288.
122. Sakurai D, Kanno Y, Hase H, et al. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol. 2007;37(1):110–118.
123. Romberg N, Chamberlain N, Saadoun D, et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Investig. 2013;123(10):4283–4293.
124. Wolf AI, Mozdzanowska K, Quinn WJ, et al. Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J Clin Investig. 2011;121(10):3954–3964.
125. Jacob CO, Yu N, Sindhava V, et al. Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors. Arthritis Rheumatol. 2015;67(9):2523–2535.